Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:56:03.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new version of a clinical trial study, including the addition of a new principal investigator and collaborators, while significant details about the trial's objectives and treatment protocols have been removed.
    Difference
    61%
    Check dated 2025-04-16T02:09:11.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from 2025-03-25 to 2025-02-19.
    Difference
    0.3%
    Check dated 2025-04-08T23:35:45.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T18:51:14.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The webpage has updated its date references to include new dates in 2025 while removing older dates from 2024. Additionally, a note about service performance has been removed.
    Difference
    2%
    Check dated 2025-03-03T22:17:03.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:37:03.000Z thumbnail image

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.